Maneesh Pharmaceuticals Limited

What Maneesh Pharmaceuticals Limited does

Maneesh Pharmaceuticals Limited is a privately held Indian pharmaceutical manufacturer and marketer founded in 1975 and headquartered in Mumbai, India. The company operates 9 state-of-the-art manufacturing facilities across Mumbai, Navi Mumbai, Pune, Hyderabad, and Solan (Himachal Pradesh), certified by US FDA (two plants), MHRA UK, and WHO Geneva GMP. Its core capabilities span oral solids, betalactams, injectables, soft gelatin capsules, hormones, anti-TB formulations, and topical dosage forms. The company also offers contract and third-party pharmaceutical manufacturing services across these dosage forms.

Commercially, Maneesh runs four dedicated marketing divisions in India: ACE (women's health, gynecology and infertility, with 350 field representatives); Inspira (orthopedics, antibiotics, anti-inflammatory, and analgesics, with 250 representatives); Maneesh Healthcare (anti-TB FDC sachets plus multi-specialty products, with 220+ executives and 1,000+ stockists); and Ergos Life Sciences (healthcare systems innovation). The Smyle consumer brand (via Svizera Health Remedies) addresses oral care and personal care retail. Notable product innovations include patented Anti-TB Fixed Dose Combination sachets (4/3/2 Drug FDC), first-in-world Amoxicillin Clavulanate with Lactic Acid Bacillus, and first-to-market immediate release Doxylamine in India. Doxinate won the Pharmarack Brand of the Year Award in 2022.

The business model rests on three pillars: domestic branded formulations sold through four divisions via an 820+ person field force; international exports to regulated markets (US, UK, EU, Australia) plus supply of Anti-TB drugs to the WHO Global Drug Facility across 77 countries; and contract/third-party manufacturing for clients including H&H (1993-2011). Revenue was not disclosed in source materials. Recent strategic moves include the 2023 acquisition of Svizera Europe to consolidate European market presence, and prior acquisitions of Phaarmasia Hyderabad (2005) for hormone/oral contraceptive manufacturing. The company operates as a private independent entity with no disclosed institutional investors and maintains a 5,000 sq ft R&D center producing approximately 15 ANDA/MA filings per year.

Name

Maneesh Pharmaceuticals Limited

Legal name

Maneesh Pharmaceuticals Ltd.

Website

https://maneeshpharma.com

Company type

Private

Founded year

1975

Operating status

Operating

Short description

Maneesh Pharmaceuticals is a privately held Indian pharmaceutical manufacturer and marketer founded in 1975, operating 9 USFDA/MHRA/WHO-GMP certified facilities across India. It sells branded formulations through four field-force divisions (women's health, orthopedics, anti-TB, healthcare systems), exports to regulated markets and supplies WHO, and offers contract manufacturing.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Pharmaceutical manufacturing
• Anti-tuberculosis drugs
• Women's health formulations
• Contract pharmaceutical manufacturing
• Oral care consumer healthcare

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract/Third Party Pharmaceutical Manufacturing: Manufacturing pharmaceutical products for third party clients including oral solids, betalactum, OTC, derma, soft gelatin capsules, effervescents, liquids, ointments, oral contraceptives and hormones
2. Branded Formulations Domestic: Marketing and selling branded pharmaceutical products through four marketing divisions: ACE (women's health), Inspira (orthopedics/antibiotics), Maneesh Healthcare (anti-TB/multi-specialty), Ergos Life Sciences
3. International Exports: Exporting pharmaceutical products to regulated markets (US, UK, EU, Australia) and supplying Anti-TB drugs to WHO Global Drug Facility in 77 countries
4. WHO/Government Supply: Supplying Anti-TB formulations to WHO Global Drug Facility and government healthcare programs globally

Go-to-market motion1 record

Distribution channels5 records

Marketing channels3 records

Core offering

Maneesh Pharmaceuticals manufactures and markets branded finished pharmaceutical formulations across women's health, orthopedics, anti-infectives, anti-tuberculosis, and consumer oral care, organized through four marketing divisions (ACE, Inspira, Maneesh Healthcare, Ergos Life Sciences) and the Svizera Health Remedies consumer brand. The company operates nine state-of-the-art manufacturing facilities with USFDA, MHRA UK, WHO Geneva, and WHO GMP certifications and additionally offers contract manufacturing for third-party clients across multiple dosage forms including oral solids, betalactams, soft gelatin capsules, injectables, hormones, and topical products.

Product overview

Maneesh Pharmaceuticals Ltd. is a leading Indian pharmaceutical company founded in 1975 with a comprehensive product portfolio organized across multiple marketing divisions and contract manufacturing services. The company operates four main marketing divisions: ACE Division (women's health, gynecology, and infertility products including Doxinate, Clofert, Femarelle, and Elferri); Inspira Division (orthopedic, antibiotics, anti-inflammatory, and analgesic products including Febrinil, Boostim, Flanzen, Si-Fixim, and Arrestin); Maneesh Healthcare Division (anti-TB formulations including the innovative 4/3/2 Drug FDC sachet range, plus Duoflam, MCV, and Retherma); and Ergos Life Sciences (healthcare innovation systems). Additionally, Svizera Health Remedies offers consumer healthcare products under the Smyle brand for oral care and personal care. The company also provides third-party pharmaceutical manufacturing services across nine facilities capable of producing tablets, capsules, creams, ointments, syrups, injections, and hormonal products.

Differentiator

Problem solved

Functional benefit

Brands

• Zypcare Lifesciences: Marketing division focused on women's health, gynecology, infertility, anti-tuberculosis, and general healthcare products.
• ACE Division
• Inspira
• Maneesh Healthcare
• Ergos
• Ergos Life Sciences
• Svizera Health Remedies
• Smyle

Products and services

• ACE Division (Zypcare Lifesciences) Marketing division focused on women's health, gynecology, and infertility, promoting brands such as Doxinate, Clofert, Femarelle, Elferri, Camforte, Ebexid, LactoFlow, Anolet, and ED. Operates a field force of 350 representatives reaching gynecologists, infertility specialists, and general practitioners across India.
• Doxinate Antiemetic product line for nausea and vomiting during pregnancy containing Doxylamine Succinate, available across multiple variants (XT, Plus, OD, Forte, G) for obstetric and gynecological prescribing.
• Clofert Clomifene citrate oral medication used to treat male and female infertility, marketed under the ACE Division for specialists and gynecologists.
• Femarelle Women's supplement line for menopausal symptoms and estrogen deficiency, sold under dedicated Femarelle Rejuvenate, Recharge, and Unstoppable SKUs.
• Inspira Division Marketing division focused on orthopedic, antibiotic, anti-inflammatory, analgesic, antipyretic, nutraceutical, and anti-tussive products, with a field force of 250 representatives reaching orthopedicians, physicians, surgeons, dentists, and pediatricians.
• Febrinil Paracetamol-based analgesic and antipyretic brand available in tablets, suspension, drops, and IV/IM injectable formulations across Inspira Division.
• Boostim Amoxicillin-clavulanate antibacterial product for respiratory tract infections, available in tablets, dry syrups, and IV injection formulations including Boostim LB 375, LB 625, and LB SR 1000.
• Flanzen Serratiopeptidase enteric-coated anti-inflammatory product for pain relief and swelling reduction, available in 2.5mg, 5mg, and 10mg tablets plus combination products.
• Maneesh Healthcare Division Multi-specialty marketing division known for patented Anti-TB Fixed Dose Combination sachets along with pain management, anti-infective, anti-emetic, and respiratory products. Operates with 220+ field executives and 1,000+ stockists covering India.
• 4 Sachet Range (Anti-TB FDC) Patented anti-tuberculosis Fixed Dose Combination product range in single-dose sachets (2, 3, 3LW, 4+, 4LW+) combining Rifampicin, Isoniazid, Ethambutol, Pyrazinamide, and Vitamin B6.
• Duoflam Pain management brand combining paracetamol, mefenamic acid, diclofenac, aceclofenac, serratiopeptidase, and topical analgesic ingredients across oral and topical formulations.
• Ergos Life Sciences Division Healthcare innovation division focused on ergonomically oriented healthcare systems and process improvements for doctors, patients, and service professionals.
• Svizera Health Remedies Division (Smyle brand) Consumer oral care and personal care products division under the Smyle brand umbrella, covering mouth ulcer gel, cough and sore throat reliever, herbal toothpaste, hand sanitizer, talc, mouth freshener, and throat drops.
• Smyle Oral Care Range Consumer oral care and personal care product range including Smyle Mouth Ulcer Gel, Cough and Sore Throat Reliever, Throatdrops, Herbal Toothpaste, Toothbrush, Refreshing Talc, Wet Wipes, Hand Sanitizer (Clinhand-H), Mouth Freshener (Sviz Minto), and Fast-Aid Medical Plaster.
• Third-Party Pharmaceutical Manufacturing Contract and third-party pharmaceutical manufacturing services covering oral solids, betalactams, OTC, derma, soft gelatin capsules, effervescents, liquids, ointments, oral contraceptives, and hormones. Operates through nine manufacturing facilities with USFDA, MHRA UK, WHO Geneva, WHO GMP, ANVISA Brazil, and AGES Austria certifications.

Quantifiable outcome

• 4 million TB cases cured in 4 years as sole WHO supplier
• +1 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Svizera EuropecoreChannel Partner/ Reseller/ Distributor · 1 January 2023In 2023, Maneesh Pharmaceuticals acquired Svizera Europe, strengthening their European market presence and distribution capabilities.
• WHO Global Drug FacilitycoreChannel Partner/ Reseller/ Distributor · 1 January 2001Svizera was the sole supplier to WHO for first four years of the Anti-TB program. Started supplying Anti-TB drugs to 77 countries through WHO Global Drug Facility.
• Medical Export Group (Netherlands)coreStrategic or Co-development Partner · 1 January 1998Tie-up with Medical Export Group, The Netherlands in 1998. This business was later regrouped as Svizera Europe as a Joint Venture with one of the founders of MEG. Svizera Europe serves as the company's European market presence.
• H&H (derma company)minorStrategic or Co-development Partner · 1 January 1993Partnership with H&H to develop and manufacture their derma products starting 1993. H&H is now the No. 2 derma company in India. All their products till 2011 were developed and manufactured by Maneesh.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Mankind Pharma: India-focused pharma company with a deep domestic field force, OTC-heavy portfolio and strong women's health brands (e.g., Mankind's gynecology/skincare lines). Closest analogue to Maneesh's ACE division go-to-market model.
• Alkem Laboratories: Indian pharma with strong anti-infective, pain management and women's health portfolios, plus USFDA-approved manufacturing. Comparable therapeutic mix (antibiotics, analgesics, gynecology) and Indian market reach.
• Lupin: Large Indian generics manufacturer with USFDA-approved facilities, ANDA pipeline and a comparable women's health / anti-infective portfolio. Overlaps directly with Maneesh's respiratory, antibiotic and women's health franchises at a much larger scale.
• Aurobindo Pharma: Large Indian generics manufacturer with extensive USFDA footprint, ANDA pipeline and global anti-infective franchises. Comparable on regulated-market strategy, manufacturing scale, and anti-infective product overlap.
• Cipla: Indian pharma major with historic leadership in anti-TB drugs supplied through global donor programmes (WHO/Global Fund) and a broad respiratory/anti-infective portfolio. Comparable on anti-TB franchise and regulated-market ambitions, but far larger and publicly listed.
• Glenmark Pharmaceuticals: Indian pharma with branded formulations, respiratory and dermatology franchises, plus US generics. Comparable therapeutic breadth and India-plus-regulated-market mix, but at significantly larger scale.
• Zydus Lifesciences (Cadila Healthcare): Diversified Indian pharma with women's health, anti-infectives, biosimilars and US generics. Overlaps with Maneesh on women's health (oral contraceptives) and antibiotic/anti-infective portfolios at greater scale.

Direct peers

• Strides Pharma Science: Indian pharma focused on generics with USFDA-approved facilities and a strong global health/tender business (anti-TB and anti-malarials). Closely comparable on regulated manufacturing footprint and donor-funded supply model.
• Macleods Pharmaceuticals: Privately-held Indian pharma manufacturer with comparable mid-tier scale, multi-therapeutic portfolio (anti-TB, antibiotics, anti-malarials) and WHO GDF supply presence. Closest analogue in size, ownership structure and anti-TB franchise overlap.
• Ipca Laboratories: Indian mid-tier pharma with a strong anti-malarial and anti-TB franchise, API-plus-formulation model, and active global health donor business. Directly comparable on WHO GDF-backed anti-infective supply and multi-plant manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maneesh Pharmaceuticals Limited